Teva Pharmaceutical Industries Limited (TEVA) Stock Profile & Financial OverviewTeva Pharmaceutical Industries Limited
TEVA Company Overview & Business Description
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.
Key Information
Current Trend for TEVA
An assessment of the current trend environment for TEVA, based on the latest closing price data and intended to describe the market context heading into the next trading session.
As of 2025-12-24, the current trend for TEVA is a Strong Momentum Environment (High Conviction Uptrend).
Daily and weekly trends are in bullish alignment, forming a strong medium-term uptrend.
- The weekly backdrop provides strong tailwinds, confirming that the medium-term path of least resistance is upward.
- Price is currently trending at a healthy distance, sitting 1.15 ATR away from the adaptive KAMA baseline.
- Technical Update: Price has breached a key Fractal High, confirming a structural breakout to the upside.
Explore More Data
Adaptive Trend Model · Daily & Weekly (2025-12-24 ET)
This model uses an adaptive trend algorithm based on daily and weekly price data to identify whether a stock is in an uptrend, downtrend, or consolidation over a multi-week to multi-month horizon. Compared with traditional moving-average systems, it filters short-term noise more effectively, captures trend continuation more reliably, and provides a stronger basis for position sizing and risk-management decisions such as stop-loss and take-profit levels.
As of 2025-12-24, TEVA in a strong expansion phase; Long-term trend is bullish.
Trend Strength: TEVA last closed at 31.74, trading 1.2 ATR above the adaptive KAMA baseline (30.89). Technical Classification: Confirmed High-Momentum Uptrend.
Trend Score: Technical Score: 95/100. Classification: Strong/Established. Alignment: High. Logic: Full multi-timeframe alignment with strong momentum filters.
SuperTrend Risk: Structural Support: Adaptive SuperTrend at 27.16. This level serves as the calculated invalidation point for the current upward structure.
Risk Skew: Multi-timeframe risk skew is currently assessed as Constructive Upside. Daily and weekly trends are in high-quality alignment with healthy momentum. Risk skew favors continued upside follow-through from current levels.
Key Levels: In this bullish structure, key support is anchored by immediate support (KAMA) at 30.89, with the critical trend-guard (SuperTrend) at 27.16.